Redefining Biotech Through Bitcoin and Breakthrough Science

Investor Summary | 2025

Transforming the $1.6 Trillion Pharma Industry with Polyphenol-Based Drug Innovation — and Redefining How It’s Funded

Canurta Therapeutics is pioneering a new era in botanical medicine. We develop novel drugs from rare polyphenols—such as Cannflavin A & B—to address inflammatory and neurological conditions, beginning with ALS.

To fund this mission, we employ a resilient, growth-oriented capital approach we call The Satoshi Trials™ — a Bitcoin-backed treasury strategy designed to protect and grow shareholder value over biotech’s long development timelines.

Key Highlights

Innovative Pipeline

CNR-401 leads a growing pipeline targeting ALS, Alzheimer’s, and inflammation—built on multi-pathway compounds and validated preclinical data.

Breakthrough Compounds

Cannflavins A & B—30x stronger than aspirin—are exclusive to Canurta.

Regulatory & Market Traction

Orphan Drug paths in the U.S. and EU, with global entry points in Australia, Canada, Brazil and Germany.

AI-Driven Drug Development

PolyKye™ AI platform accelerates discovery by predicting high-value therapeutic targets and optimizing molecule selection, improving success rates and expanding the pipeline.

Strategic Merger Pathway

In process of amalgamation with PHRX/extractX to expand manufacturing capabilities, accelerate market access, and list on the Canadian Securities Exchange.

Dual-Upside Capital Model

Bitcoin-backed treasury strategy designed to preserve capital over long clinical timelines, reduce dilution through BTC-backed lending, and offer shareholders exposure to both biotech breakthroughs and Bitcoin appreciation.

Pioneers in Botanical Therapeutics

Canurta Day Video Series Email Image.jpg

Founded in 2021, Canurta develops polyphenol-based drugs for neurological and inflammatory conditions. Our lead candidate, CNR-401, enters ALS trials in 2025 with early commercial programs in Brazil and Germany. Backed by over $13M in capital and $3.22M in non-dilutive funding, global IP, and GMP infrastructure, we are bridging nature with next-generation medicine.

Our capital strategy, The Satoshi Trials™, leverages Bitcoin not just as a reserve, but as a long-term growth engine. With 1.35 BTC already in reserve and a 5-year plan to accumulate 500 BTC, we are aligning digital asset growth with ALS innovation. Based on a 28.9% CAGR projection, our Bitcoin reserves could exceed $9B CAD by 2046.

This dual approach extends our R&D runway, reduces dilution, and positions Canurta as a pioneer in asset-backed biotech funding — giving shareholders exposure to both life-changing therapeutics and Bitcoin’s exponential potential.

The Satoshi Trials™ – A Dual-Engine Growth Model

The Problem

Biotech innovation demands long development timelines and significant capital. Traditional funding models rely on repeated equity raises, which dilute shareholder value. Cash reserves lose purchasing power over time due to inflation, putting additional strain on R&D budgets and long-term planning.

The Solution

The Satoshi Trials™ transforms biotech financing by anchoring our treasury in Bitcoin — a scarce, appreciating asset with a fixed supply. Instead of depleting reserves, we hold BTC and use it as collateral for operational funding. As Bitcoin’s value grows, so does our borrowing capacity, creating a self-reinforcing cycle that funds R&D while preserving ownership. This dual-growth model combines the upside of breakthrough therapeutics with the compounding effect of a strong, inflation-resistant balance sheet — a financial strategy built for biotech’s long game.

Key Facts

Current BTC Holdings: 1.35 BTC (as of July 9, 2025)

5-Year Target: 500 BTC — projected value >$9B CAD by 2046 (28.9% CAGR)

Performance: +10.26% total BTC return since inception; +7.58% YTD (as of June 30, 2025)

Strategic Partnerships: PHRX merger & ExtractX integration add infrastructure, public market access, and diversified revenue streams.

500 BTC valued at $9B by 2046

The Case for Bitcoin

Bitcoin is the world’s first decentralized digital asset, with a fixed supply of 21 million coins and a growing role in corporate and institutional portfolios. It is scarce, secure, and borderless — making it a compelling choice for a long-term treasury reserve strategy.

Proven Performance: Bitcoin has been the best-performing asset of the last decade, with stronger long-term returns than equities, bonds, and commodities.
Institutional Momentum: Public companies like MicroStrategy, Semler Scientific, and Metaplanet have successfully adopted Bitcoin treasury strategies, using it to build shareholder value and attract new investor bases.
Macro Relevance: With inflation eroding the value of cash reserves, Bitcoin offers a hedge against currency debasement and a store of value unlinked to traditional financial systems.
Liquidity and Market Depth: Bitcoin trades 24/7 with deep global liquidity, making it one of the most accessible and transferable assets in existence.

As adoption accelerates across public markets, ETFs, and sovereign entities, the long-term case for Bitcoin continues to strengthen — making it an ideal complement to Canurta’s biotech growth engine.

CNR-401: A Botanical Breakthrough for ALS

CNR-401 is a proprietary liquid botanical drug composed of 10 active compounds, including cannflavin A, designed to relieve symptoms and slow disease progression in ALS and other neurodegenerative diseases. First-in-human trials will begin in 2025.

CNR-401: Neurodegenerative Care | Canurta Therapeutics

CBD

Other Minor Constituents

Terpenoids

CFA

Preclinical Highlights

Restored 85% motor function in zebrafish ALS model

Broader gene modulation than Edaravone, including NOS2 and DOCK2

Reduced anxiety-like behavior by 80%, with effects comparable to CBD

Confirmed non-toxicity at therapeutic doses

Mechanism of Action (MoA)

CNR-401 targets multiple systems impacted by ALS:

Neuron Survival – Anti-inflammatory, reduces glutamate toxicity

Motor Function – Enhances spasticity, coordination, and strength

Respiratory Health – Improves lung function and secretion clearance

Cognitive & Emotional – Reduces anxiety and supports mood

Cellular Defense – Boosts mitochondrial and antioxidant function

CNR-401 vs. Standard ALS Therapies

Feature	CNR-401	Edaravone	Riluzole
Annual Cost	~30K CAD (NA)	~$185K	~$5.4K
IP & Exclusivity	Global patents + 7-10 yrs exclusivity	Expired	Expired
Regulatory Path	Botanical + Orphan	Small molecule	Small molecule
Mechanism	Multi-target	Single Target: Free radical scavenger	Single Target: Glutamate inhibition
Symptom Relief	Broad	None	Limited
Disease Modification	Strong Potential	Modest	Modest
Safety Profile	Oral, favorable	IV, known side effects	Requires live monitoring

The Backbone: Cannflavins

Cannflavins A & B are rare polyphenols with 30x the anti-inflammatory potency of aspirin. They inhibit key enzymes like mPGES-1 and 5-LO, showing efficacy comparable to Zileuton, with broader therapeutic potential across neuroprotection and pulmonary health. Canurta holds exclusive global IP across extraction, formulation, and therapeutic use.

The Engine: Polykye™

PolyKye™ is Canurta’s proprietary AI platform that transforms rare plant compounds into next-gen therapies. It predicts compound behavior, adapts based on lab and clinical data, and enables ongoing optimization—cutting R&D timelines and powering a continuously evolving pipeline. Blockchain tracking across development stages ensures data integrity and transparent decision-making.

Therapeutic Pipeline

Canurta leverages patented technology to unlock the blockbuster potential of rare polyphenols, creating multi-target, disease-specific formulations for inflammatory and neurological diseases. Its lead molecules, cannflavins A and B, serve as the foundation for breakthrough therapies.

Asset Growth Meets Capital Efficiency

CNR-401 and CNR-101 are projected to grow from $170M to nearly $60B in rNPV via FDA-driven commercialization. Canurta’s platform supports this growth with speed, resilience, and capital efficiency, built to scale while preserving long-term upside through:

Scalable Manufacturing (ExtractX): Mobile labs enhance speed, global market flexibility, and de-risked production capacity.

Non-Dilutive Growth Capital (BTC Collateral): 30–50% LTV BTC-backed liquidity unlocks growth without equity dilution.

Balanced Asset Allocation (Canurta LP + PHRX): 60% Canurta LP / 40% PHRX supports both runway and innovation.

CNR-401(+): rNPV growth from $101K (2024) to $17.1B (2040), fueled by ALS market entry & FDA milestones.

CNR-101: rNPV increase from $169M (2024) to $39.9B (2037) — a 236x return potential across multiple indications.

When paired with the Satoshi Trials™ Bitcoin accumulation model, these biotech valuations benefit from an appreciating, non-correlated treasury — creating asymmetric upside beyond clinical milestones.

Invest Where Innovation Meets Bitcoin

Canurta is building a new era of medicine—leveraging rare polyphenols to combat devastating diseases, and Bitcoin to strengthen our financial foundation.

Together, we can create therapies that change lives and a treasury built for the future.

Book a Call